Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03168412
Other study ID # PRO-HE-008
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 25, 2017
Est. completion date November 28, 2018

Study information

Verified date February 2019
Source Xiamen Innovax Biotech Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase IV clinical study was designed to evaluate the immunogenicity and safety of the recombinant Hepatitis E vaccine (Hecolin®), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy adults (over 18 years) with accelerated vaccination schedule. The study volunteers will receive the 3 doses of Hecolin® administered intramuscularly according to a 0-7-21 days schedule or a 0-1-6 month schedule.


Recruitment information / eligibility

Status Completed
Enrollment 125
Est. completion date November 28, 2018
Est. primary completion date July 15, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Aged over 18 years old on the day of enrollment, including 18 years old;

2. Axillary temperature is below than 37.0 ?;

3. Negative serological markers for hepatitis E and liver function are normal or no clinical significance;

4. Judged as healthy and eligible for vaccination by the investigators through a selfreported medical history and some physical examinations;

5. Able to understand this study information and willing to comply with all study requirements;

6. Willing to participate in this study and sign informed consent form.

Exclusion Criteria:

1. Pregnancy,breast-feeding or plan to be pregnant in 7 months;

2. Administration of Hepatitis E Vaccine before the study;

3. Participate in any other clinical trial during the study period;

4. Use of any investigational product or non-registered product (drug or vaccine)within 30 days preceding the first dose of the study vaccine or plan to use during the study period;

5. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment;

6. Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine,or plan to use during the study period;

7. Administration of any inactivated vaccines within 14 days preceding the first dose of the study or attenuated live vaccines within 21 days preceding the first dose of the study;

8. Had a fever (axillary temperature over 38°C) within 3 days or acute illness, or use systemic antibiotics or antiviral treatment within 5 days before vaccination;

9. Immunodeficiency (such as HIV carriers), primary disease of important organs, malignant tumor, or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response), liver and kidney disease and other chronic disease history;

10. History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy,urticaria, dyspnea, angioneurotic edema or abdominal pain. Allergic history to any component of this vaccine.

11. Asthma that needed emergency treatment, hospitalization, oral or intravenous corticosteroid to keep stable in the past two years;

12. Combining another severe internal medicine disease(such as cardiopathy,diabetes and hyperthyroidism)

13. Anormal coagulation function or coagulopathy diagnosed by doctor;

14. Epilepsy(not including alcohol epilepsy within 3 years prior to abstinence and simple epilepsy that do without curing within 3 years prior to the study )

15. Anomal psychology or mind affecting the individual's ability to obey the study requirement;

16. Other medical, psychological, social or occupational factors that, according to the investigators' judgment,might affect the individual's ability to obey the protocol or sign the informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Recombinant Hepatitis E Vaccine (Escherichia Coli)
Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
Recombinant Hepatitis E Vaccine (Escherichia Coli)
Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.

Locations

Country Name City State
China Changshan Center for Disease Control and Prevention Quzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Xiamen Innovax Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Anti-HEV antibody of Experimental Group Measure anti-HEV antibody in serum samples at 51st day to evaluate the immunogenicity of the Hepatitis E vaccine. up to 2 months
Secondary Adverse reactions/events of Experimental Group and Control Group Measure solicited local adverse reactions/events within 7 days after each vaccination; Measure solicited systematic adverse reactions/events within 7 days after each vaccination; Measure unsolicited adverse reactions/events within 30 days after vaccination; Measure serious adverse events occurred throughout the study(up to 7 months). up to 7 months
Secondary Anti-HEV antibody of Experimental Group Measure anti-HEV antibody in serum samples at 21st day,28st day and month 7 to evaluate the immunogenicity of the Hepatitis E vaccine. up to 7 months
Secondary Anti-HEV antibody of Control Group Measure anti-HEV antibody in serum samples at month 1,2,7 to evaluate the immunogenicity of the Hepatitis E vaccine. up to 7 months
See also
  Status Clinical Trial Phase
Completed NCT03365921 - A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial) Phase 4
Completed NCT02584543 - A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine) Phase 4
Not yet recruiting NCT03488589 - HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver
Completed NCT03601221 - Seroprevalence Hepatitis E Infection in Healthy Blood Donors
Completed NCT02189603 - Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®) Phase 4
Completed NCT02847507 - Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb)
Completed NCT02603055 - A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults Phase 1
Completed NCT02190253 - Seroprevalence of Hepatitis E in People With an Organ Transplant
Recruiting NCT06457438 - Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors N/A
Completed NCT04670419 - Morbidity and Mortality of Hepatitis E Virus Infections in Belgium
Completed NCT03282474 - HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE) Phase 2
Terminated NCT02558114 - Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection. Phase 4
Recruiting NCT06137313 - Exposure to Hepatitis E Virus in Occitania, France
Completed NCT02964910 - A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients ) Phase 4
Completed NCT01014845 - Clinical Trial of Recombinant Hepatitis E Vaccine Phase 3
Recruiting NCT05976594 - Long-term Effectiveness of a Recombinant Hepatitis E Vaccine
Completed NCT02417597 - A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli) Phase 4
Completed NCT03827395 - Safety Study of Hepatitis E Vaccine (HEV239) Phase 1